Sanofi Biotechnology;Regeneron Pharmaceuticals, Inc.
发明人:
SCHWARTZ, Gregory,PORDY, Robert,BESSAC, Laurence,HANOTIN, Corinne,SASIELA, William,STEG, Philippe
申请号：
AU2019231703
公开号：
AU2019231703A1
申请日:
2019.03.06
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
The present invention provides methods for treating diseases and disorders that are associated with elevated levels of lipids and lipoproteins. The methods of the present invention comprise administering to a high cardiovascular risk patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P or alirocumab. The methods of the present invention are useful for treating high cardiovascular risk patients with hypercholesterolemia and elevated levels of other atherogenic lipoproteins that are not adequately controlled by maximum tolerated dose statin therapy. In particular, the methods of the present invention are useful for reducing cardiovascular risk and lowering atherogenic lipoproteins in high cardiovascular risk patients within 12 months following an acute coronary syndrome event despite a maximum tolerated dose statin therapy.
